Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20980337 | 0.84 | STK17B (0.44) | STK17BSTK17ADGAT1 | |
| SCHEMBL22994942 | 0.84 | STK17B (0.44) | STK17BSTK17ADGAT1 | |
| SCHEMBL20959224 | 0.78 | P2RX7 (0.33) | STK17BSTK17ASLC6A4SLC6A3 | |
| SCHEMBL20959223 | 0.78 | P2RX7 (0.33) | STK17BSTK17ASLC6A4SLC6A3 | |
| SCHEMBL20926997 | 0.71 | STK17B (0.47) | STK17BSTK17ASYK | |
| SCHEMBL20926950 | 0.69 | STK17B (0.46) | STK17BSTK17A | |
| SCHEMBL24052729 | 0.67 | LATS1 (0.41) | STK17BSTK17A | |
| SCHEMBL20980340 | 0.67 | STK17B (0.38) | STK17BSTK17A | |
| SCHEMBL20980348 | 0.67 | STK17B (0.38) | STK17BSTK17A | |
| SCHEMBL14976387 | 0.65 | SYK (0.42) | STK17BSTK17ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | STK17B 819/4885STK17A 1110/4885SYK 4263/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | STK17B 897/4885STK17A 1014/4885SYK 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.